Kirkham Sara, Sheehan John K, Knight David, Richardson Paul S, Thornton David J
Wellcome Trust Centre for Cell-Matrix Research, University of Manchester, School of Biological Sciences, 2.205, Stopford Building, Manchester M13 9PT, UK.
Biochem J. 2002 Feb 1;361(Pt 3):537-46. doi: 10.1042/0264-6021:3610537.
Respiratory mucus contains a mixture of gel-forming mucins but the functional significance of these different mucin species is unknown. To help gain a better understanding of mucus in airways we therefore need to ascertain the concentration of each of the gel-forming mucins within respiratory secretions. Thus the aim of this study was to determine the amounts of specific gel-forming mucins directly from solubilized secretions of the airways and purified mucin preparations. We investigated the feasibility of using direct-binding ELISA employing mucin-specific antisera but were unable to obtain reliable data owing to interference with the immobilization of the mucins on the assay surface by 6 M urea and high levels of non-mucin proteins. We therefore developed an alternative approach based on quantitative Western blotting after agarose-gel electrophoresis, which was not subject to these problems. Here we demonstrate that this procedure provides reliable and reproducible data and have employed it to determine the amounts of the MUC2, MUC5AC and MUC5B mucins in saline-induced sputa from healthy airways and spontaneous sputa from asthmatic airways. Additionally we have used this procedure to analyse these glycoproteins in mucin preparations purified from cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) mucus. Our findings indicate that MUC5AC and MUC5B are the major oligomeric mucins and that airways mucus contains variable amounts of these glycoproteins. By contrast, the MUC2 mucin comprised, at most, only 2.5% of the weight of the gel-forming mucins, indicating that MUC2 is a minor component in sputum. Finally, we show that the amounts and glycosylated variants of the MUC5AC and MUC5B mucins can be altered significantly in diseased airways with, for instance, an increase in the low-charge form of the MUC5B mucin in CF and COPD mucus.
呼吸道黏液含有多种形成凝胶的黏蛋白,但这些不同种类黏蛋白的功能意义尚不清楚。因此,为了更好地了解气道中的黏液,我们需要确定呼吸道分泌物中每种形成凝胶的黏蛋白的浓度。因此,本研究的目的是直接从气道的可溶性分泌物和纯化的黏蛋白制剂中测定特定形成凝胶的黏蛋白的含量。我们研究了使用黏蛋白特异性抗血清进行直接结合ELISA的可行性,但由于6 M尿素和高水平的非黏蛋白蛋白干扰黏蛋白在检测表面的固定,未能获得可靠数据。因此,我们开发了一种基于琼脂糖凝胶电泳后定量蛋白质免疫印迹的替代方法,该方法不存在这些问题。在这里,我们证明该方法提供了可靠且可重复的数据,并已用它来测定健康气道盐水诱导痰液和哮喘气道自发性痰液中MUC2、MUC5AC和MUC5B黏蛋白的含量。此外,我们还使用该方法分析了从囊性纤维化(CF)和慢性阻塞性肺疾病(COPD)黏液中纯化的黏蛋白制剂中的这些糖蛋白。我们的研究结果表明,MUC5AC和MUC5B是主要的寡聚黏蛋白,气道黏液中这些糖蛋白的含量各不相同。相比之下,MUC2黏蛋白最多仅占形成凝胶的黏蛋白重量的2.5%,这表明MUC2是痰液中的次要成分。最后,我们表明,在患病气道中,MUC5AC和MUC5B黏蛋白的含量和糖基化变体可能会发生显著变化,例如,CF和COPD黏液中MUC5B黏蛋白的低电荷形式会增加。